Form 4: Replimune Group Director Acquires Stock Options
SEC Form 4 Filing
Christy J. Oliger, a director of Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2025, at an exercise price of $8.40.
Summary
- On April 1, 2025, Christy J. Oliger, a director of Replimune Group, Inc., acquired stock options for 32,000 shares.
- The exercise price of these options is $8.40 per share.
- The options vest entirely on April 1, 2026, and expire on April 1, 2035.
- Following the transaction, Oliger directly owns options for 32,000 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company directors.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of transaction: Christy J. Oliger acquired stock options. |
| 04/01/2026 | Vesting date: The shares underlying the options vest entirely. |
| 04/01/2035 | Expiration date: The stock options expire. |
| 04/03/2025 | Date of signature. |
Keywords
Replimune Group, stock options, director, acquisition, Form 4, Oliger, REPL
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.